BioCentury
ARTICLE | Company News

MiReven, Silence Therapeutics deal

August 27, 2012 7:00 AM UTC

Silence partnered with MiReven to develop formulations of MiReven's microRNA-7 (miR-7) using Silence's lipid-based delivery technologies. The partners will evaluate the compound in models of prostate and lung cancers and melanoma. Silence will receive an undisclosed fee for the deal. MiReven said both parties will have a commercial interest in products from the deal, but the company did not disclose details.

Silence will apply its AtuPLEX, DACC and DBTC delivery technologies. AtuPLEX delivers therapeutics to vascular endothelial cells, DACC delivers to the lung endothelium, and DBTC delivers to the liver. ...